Trevena, Galderma, Santaris and others see executive changes in this week’s People on the Move column.
Erez Vigodman has been picked to become Teva Pharmaceutical Industries CEO from February 11.
He replaces Jeremy Levin, who resigned unexpectedly in October 2013, days after denying rumours of his departure.
At that time, Teva began a cost-cutting program to save $2bn (€1.48bn) by 2017, including a “headcount reduction target” of 5,000 jobs planned to take effect this year.
Vigodman, 54, was previously CEO of Makhteshim Agan Industries, the world's largest generic pesticides company, from 2010.
But an unnamed analyst told Reuters the agrochemical and pharmaceutical industries are very different, and Vigodman will have to work to reassure investors:
"The timeline to bring out new pharmaceutical products is a different ball game. It's not the same regulatory issues and it's more complicated," said the analyst.
Teva’s chairman Phillip Frost welcomed Vigodman, saying “As a member of the Teva Board since 2009, Erez has a deep understanding of the company and the industry in which it operates, putting him in a strong position to hit the ground running and deliver value for shareholders.”
Copyright - Unless otherwise stated all contents of this web site are © 2016 - William Reed Business Media SAS - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions
Eli Lilly is conducting several experiments on the International Space Station (ISS) US National Laboratory over the...
The world’s largest modular cGMP biopharmaceutical manufacturing facility came online this week in Wuhan, China.
Valeant, Rentschler, Celgene, MannKind, and Syngene are among those welcoming new leaders for 2016. Oh, and Turing...